mXELOXIRI Combined With Molecular Targeted Drug in mCRC

NCT04160416 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

48

Enrollment

OTHER

Sponsor class

Conditions

Unresectable Metastatic Colorectal Cancer

Interventions

DRUG: Capecitabine-Oxaliplatin-Irinotecan Combination

Sponsor

First Affiliated Hospital of Zhejiang University